ONCIN.OL Oncoinvent ASA

Healthcare Biotechnology Oslo Stock Exchange
67.80 NOK
Close of Nov 4, 2026
40.10 144.00
Market cap
NOK 416M
P/E
-
P/B
4.97x
ROE
-106.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ONCIN.OL undervalued?

Graham number

The Graham number of Oncoinvent ASA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oncoinvent ASA fundamental analysis

No fundamental analysis for Oncoinvent ASA yet.

Oncoinvent ASA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Full company profile